Bristol Myers Squibb Engage with instructors and fellow students for half-day or up to three-day programs in a virtual or classroom setting. endobj Gregorian year (common era) Hebrew year. Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. And while our work transforms the lives of patients, it also transforms the lives and careers of those who do it. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. 0000003062 00000 n The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $4.1 billion, or $1.83 per share, in the fourth quarter, compared to non-GAAP net earnings of $3.3 billion, or $1.46 per share, for the same period a year ago. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023, Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share, Expected to be Accretive to Non-GAAP Earnings Per Share beginning in 2025. We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. #BMSCareers. 0000013257 00000 n This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point Therapeutics by the company and the development and commercialization of certain biological compounds. Tuition reimbursement is available to eligible employees who, through their own initiation and desire for development, participate in accredited educational programs that their manager deems will be mutually beneficial to BMS and the employee. 0000193195 00000 n Play. The website may also contain certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. A dds details on agreement, background. Stress management, well-being, and integrating work with life all determine the energy we bring each day to our work, family and community. 0000042941 00000 n None of our operations have been identified as having significant risk for incidents of child labor or forced labor. A replay of the conference call will be available beginning at 11:30 a.m. Tuesday, November 16, 2021. 0000002184 00000 n The 2022 Country 2 Country 4 Cancer ride organised by Bristol Myers Squibb will feature more than 90 of the company's employees cycling in seven European countries from 2-19th September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. Available to US-based employeesChange location, Comparable to many others in the same league. Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. Play. 0000010800 00000 n In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset, said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. bristol myers squibb holiday calendar 2021. Research and development expenses decreased 30% to $2.6 billion in the quarter. 0000002307 00000 n Japan's Ministry of Health, Labour and Welfare also accepted the NDA for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis, pustular psoriasis and erythrodermic psoriasis. Bristol Myers Squibb is well positioned to build on our success in 2021 and continue to grow our company through the end of the decade. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. The benefit choices you make go into effect each January 1 (or on your date of eligibility, if later), and stay in effect through December 31, as long as you remain eligible for benefits. squibb bristolmyers bristol myers pharma pharmaceutical culture balance more Ok but hard to move within the company Analyst (Former Employee) - Tampa - February 4, 2023 Indeed Featured review Always evolving due to the industry. 0000043107 00000 n Bristol Myers Squibb Paid Holidays 106 employees reported this benefit 4.3 20 Ratings Available to US-based employees Change location Employee Comments Showing 1-10 of 20 Jan 28, 2023 4.0 Current Direcror in nullnull Comparable to many others in the same league Helpful Report Dec 22, 2022 4.0 We foster an energizing work experience, that through your choices, education and access, sustains our environment of well-being, individual accountability, productivity and safety. 07/29/21 : Interim 2021 Earnings Release (Projected) 10/28/21 : Q3 2021 Earnings Release (Projected) 01/27/22 : FY 2021 Earnings Release (Projected) 04/28/22 Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Working among other smart, creative and talented colleagues, youll find support and uncommon opportunities to learn, grow and lead. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. rotating shift 36/48, which involves working all holidays that fall on the schedule. Minor Fasts . The case is UMB Bank NA v Bristol-Myers Squibb (NYSE: BMY) Co et al, U.S. District Court, Southern District of New York, No. Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics common stock at a price of $76.00 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. ET on April 29, 2021 Bristol-Myers Squibb (NYSE:BMY) SVP Adam Dubow sold 3,119 shares of the business's stock in a transaction dated Wednesday, May 5th. Moving to the bottom line, Bristol Myers Squibb grew its non-GAAP EPS by 22.7% YOY to $2.00 in the third quarter. Gross margin increased from 73.7% to 80.3% in the quarter primarily due to an impairment charge related to marketed product rights in the same period a year ago and lower unwinding of inventory purchase price accounting adjustments. Media: media@bms.com Following the successful closing of the tender offer, Bristol Myers Squibb will acquire all remaining shares of Turning Point Therapeutics that are not tendered into the tender offer through a second-step merger at the same price of $76.00 per share. New Year's Day Martin Luther King Presidents Day Memorial Day July 4th Labor Day Thanksgiving and Day After Christmas Day Chevron Sara Kashima SKSH@chevron.com President's Day is only a holiday for those on the traditional 5/40 schedule. 1 Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 0000007256 00000 n Non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. The recognition is a testament to our commitment to transform patients lives through science. Bristol Myers Squibb is also reaffirming its previously communicated 2020-2025 long-term targets: This financial guidance excludes the impact of any potential future strategic acquisitions and divestitures as well as any specified items as discussed under Use of Non-GAAP Financial Information. There is no reliable or reasonably estimable comparable GAAP measures for this non-GAAP financial guidance. Learn more about the cookies we use on our General Privacy Notice page. July 28 (Reuters) - Bristol Myers Squibb Co (BMY.N) reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after. Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, Standards of Business Conduct and Ethics. I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. Access thousands of interactive online resources to gain the skills you need, when you need them. Selling, General & Admin. Available to US-based employeesChange location, Comparable to many others in the same league. Shareholder proposals relating to our 2021 Annual Meeting of Shareholders must be received by us at our principal executive offices, Bristol-Myers Squibb Company, 430 East 29th Street14th Floor, New York, New York 10016, Attention: Corporate Secretary, no later than November 25, 2020. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. Holiday Calendar; Earnings Calendar; A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. The Office of Corporate Conduct is a resource for any employee to confidentially and anonymously report their concerns or raise questions. 33 days holiday (inc. bank holidays) - prorated - with the option to buy/sell 5 additional days ; A replay of the webcast will be available on http://investor.bms.com approximately three hours after the conference call concludes. ET during which company executives will review financial information and address inquiries from investors and analysts. Past events. Bristol-Myers Squibb's report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared TipRanks Team May 19, 2021. With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. 0000011978 00000 n Best place for vacation and time off, BMS incentivize family time. 866 0 obj ET. Apr 27, 2021 (The Expresswire) -- Covid -19 Impact to global Stroke Treatment Drugs Market for 2015-2025. #BMSCareers. We believe in a Total Rewards experience that enriches your life today and engages and empowers you to save, perform, grow, and build toward all of your tomorrows. Add to Microsoft Outlook. Our Insights for Success program is offered to diverse employees to enhance their organizational and personal career success and ensure equitable leadership throughout the company. We routinely post important information for investors on our website, BMS.com, in the Investors section. Since our founding, we have leveraged our deep scientific expertise to develop a pipeline of promising precision oncology assets, said Athena Countouriotis, M.D., President and Chief Executive Officer, Turning Point Therapeutics. Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article . The Bristol-Myers Squibb Benefits Program gives you the flexibility and opportunity to choose from a variety of options. 0000004307 00000 n Aug 2010 - Present12 years 8 months. All comparisons are made versus the same period in 2020 unless otherwise stated. 0000012578 00000 n Learn about Bristol Myers Squibb Vacation & Paid Time Off, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. Agenus saw its stock skyrocket on Tuesday after the company announced a $1.6 billion deal with Bristol-Myers Squibb (NYSE: BMY), a $146 billion giant, to develop Agenus promising new cancer antibody treatment. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the timing of the tender offer and the subsequent merger, (ii) the number of shares of the Turning Point Therapeutics common stock that will be tendered in the tender offer, (iii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iv) the risk that legal proceedings may be instituted related to the merger agreement, (v) any competing offers or acquisition proposals for Turning Point Therapeutics, (vi) the possibility that various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the offer or the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. People and Business Resource Groups are provided mentor/mentee learning and development among employees on a global scale. 0000192879 00000 n In 2021, their top products included Revlimid and Opdivo, drugs used in the treatment of certain. Usually give off For the year end holidays too! 0000000016 00000 n 0000042527 00000 n endstream Posted: October 12, 2021 Full-Time At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.72. Investor Relations: investor.relations@bms.com, Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021, https://www.businesswire.com/news/home/20220204005037/en/, Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%, driven by. 0000043721 00000 n Bristol-Myers Squibb, one of the world's largest pharmaceutical companies, arose out of a 1989 merger and today focuses on the manufacture of prescription medicines for the treatment of cancer . In addition, the non-GAAP financial guidance in this communication excludes the impact of any potential additional future strategic acquisitions and divestitures and any specified items that have not yet been identified and quantified. No forward-looking statement can be guaranteed. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Turning Point Therapeutics common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Listen to Webcast. The companys performance in the first quarter of 2021 Furthermore, one of the three required milestones for payment of the Bristol Myers Squibb Contingent Value Right (CVR) remained unaccomplished due to the pending FDA approval as of Dec. 31, 2020. The recognition is a testament to our commitment to transform patients lives through science. Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. You may read any reports, statements or other information filed by the company or Turning Point Therapeutics with the SEC at no charge on the SECs website at www.sec.gov. Bristol Myers Squibb Paid Holidays 106 employees reported this benefit 4.3 20 Ratings Available to US-based employees Change location Employee Comments Showing 1-10 of 20 28 Jan 2023 4.0 Current Direcror in nullnull Comparable to many others in the same league Helpful Report 22 Dec 2022 4.0 Breakout Session - Bristol Myers Squibb Presents: The Future of Cancer Care: Transformative Innovation for All . Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. If you have $1,000 at the ready, pharmaceutical stock Bristol Myers Squibb *Stock Advisor returns as of June 7, 2021. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Thats why we provide a range of services, resources and encouragement to achieve and sustain good health. hb```b``{Ab,GU\r``8e/Gu sMJM ;xxDFD>]/=nxoEA2nlt2Tr2\+lcGC=!Rq(t=-SPMHj>Ytv@! There's been plenty of good news for Bristol Myers Squibb (BMY 0.13%) . Diaspora holiday schedule. (Reuters) - A judge in Hawaii on Monday ordered Bristol-Myers Squibb (NYSE: BMY) Co and Sanofi (NASDAQ: SNY) SA Following the sale, the senior vice president now directly owns 16,243 shares in the company, valued at $1,042,963.03. 0000003506 00000 n The stock's 50-day moving average price is $64.07 and its 200-day moving average price is $62.55. The same period a year ago included license and acquisition charges related to Dragonfly, an in-process research and development (IPR&D) impairment charge and cash settlement of MyoKardia unvested stock awards. Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. The basis for our security efforts is to protect our employees, operations and intellectual property. Find out why possibility lives at Bristol Myers Squibb, We demonstrate ethics, integrity and quality in everything we do for patients, customers and colleagues, We pursue disruptive and bold solutions for patients, We move together with speed and quality because patients are waiting, Our dedication to learning and excellence helps us to deliver exceptional results, We all own BMS success and strive to be transparent and deliver on our commitments, We embrace diversity and foster an environment where we can all work together at our full potential. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Meet Our Team in Tampa, FL Meet Our Team in Tampa, FL Possibility Lives at BMS Find out why possibility lives at Bristol Myers Squibb Asha on Skills 2 Give Volunteer Program Asha on Skills 2 Give Volunteer Program customer.relations@bms.com (877) 517-6326 (Monday-Friday, 8 AM-8 PM ET) Adverse event or product quality complaints (800) 721-5072 In addition to the items discussed above, the results in the same period a year ago included an IPR&D charge related to the MyoKardia asset acquisition of $11.4 billion and the impact of fair value adjustments on equity investments and contingent value rights in both periods. The study was conducted by The Bristol Myers Squibb-Janssen Collaboration. Bristol-Myers shares have gained 6.4% year to date against the industry's decline of 1.3%.. Top Key Vendor's likes - Boehringer Ingelheim, Bristol-Myers Squibb Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. Share; Facebook; Twitter; LinkedIn . Jun 13, 2021 9:01AM EDT. Investors and the public can also access the live webcast by dialing in the U.S. toll free 877-502-9276 or international +1 313-209-4906, confirmation code: 2150568. MORAb-202 is Eisais first ADC and combines Box 4000, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, for and on behalf of itself and its Affiliates Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in The firm is expected to announce its next quarterly earnings report on Thursday, August 5th. Bristol-Myers Squibb expanded its collaboration to help The Max Foundation reach 45% The biopharmaceutical company reported $1.74 earnings per share for the quarter, missing analysts' consensus estimates of $1.82 by ($0.08). Air India, part of Tata group, had signed an order for 40 GE engines, plus a multi-year engine services agreement. 0000004547 00000 n The company has a current ratio of 1.67, a quick ratio of 1.58 and a debt-to-equity ratio of 0.82. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges or other income resulting from up-front or contingent milestone payments in connection with the acquisition or licensing of third-party intellectual property rights, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this communication. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Former Sales Training Manager in nullnull, Current Senior Manufacturing Engineer in New Brunswick, NJ, New Jersey, Former Senior Financial Analyst in Princeton, NJ, New Jersey, Current Senior Cell Processing Specialist in Summit, NJ, New Jersey, Current Scientific Director in Princeton, NJ, New Jersey, Current Statistician in New Brunswick, NJ, New Jersey, Current Sourcing Manager in Tampa, FL, Florida. Security personnel receive training to ensure compliance with legal requirements and respect for human rights. We know its not easy to make a difference, so we make sure each employee feels empowered and motivated in their efforts to do so. We claim: 1. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; changes to tax and importation laws and other restrictions in the United States, the European Union and other regions around the world that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; challenges inherent in new product development, including obtaining and maintaining regulatory approval; the companys ability to obtain and protect market exclusivity rights and enforce patents and other intellectual property rights; the possibility of difficulties and delays in product introduction and commercialization; the risk of certain novel approaches to disease treatment (such as CAR T therapy); industry competition from other manufacturers; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products, including without limitation, interruptions caused by damage to the companys and the companys suppliers manufacturing sites; the impact of integrating the companys and Celgenes business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting systems, sales operations and product distribution, pricing systems and methodologies, data security systems, compliance programs and internal controls processes; the risk of an adverse patent litigation decision or settlement and exposure to other litigation and/or regulatory actions; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the companys suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; regulatory decisions impacting labeling, manufacturing processes and/or other matters; the impact on the companys competitive position from counterfeit or unregistered versions of its products or stolen products; the adverse impact of cyber-attacks on the companys information systems or products, including unauthorized disclosure of trade secrets or other confidential data stored in the companys information systems and networks; the companys ability to execute its financial, strategic and operational plans; the companys ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; the companys dependency on several key products; any decline in the companys future royalty streams; the companys ability to effectively manage acquisitions, divestitures, alliances and other portfolio actions and to successfully realize the expected benefits of such actions; the companys ability to attract and retain key personnel; the impact of the companys significant additional indebtedness that it incurred in connection with the Celgene acquisition and the MyoKardia acquisition; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; the impact of adverse outcomes in lawsuits, claims, proceedings and government investigations; the impact of our exclusive forum provision in our by-laws for certain lawsuits on our stockholders ability to obtain a judicial forum that it finds favorable for such lawsuits; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic on the companys operations.